ADPT
Adaptive Biotechnologies Corp
$
12.200
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
12.670
Open
12.620
VWAP
12.08
Vol
3.12M
Mkt Cap
1.86B
Low
11.845
Amount
37.68M
EV/EBITDA(TTM)
--
Total Shares
147.37M
EV
1.85B
EV/OCF(TTM)
--
P/S(TTM)
9.11
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
59.54M
+13.53%
-0.170
-15%
60.68M
+27.86%
-0.185
-18.72%
55.52M
+19.56%
-0.202
-6.68%
Estimates Revision
The market is revising Downward the revenue expectations for Adaptive Biotechnologies Corporation (ADPT) for FY2025, with the revenue forecasts being adjusted by -0.49% over the past three months. During the same period, the stock price has changed by 35.11%.
Revenue Estimates for FY2025
Revise Downward
-0.49%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+35.11%
In Past 3 Month
8 Analyst Rating
-2.79% Downside
Wall Street analysts forecast ADPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 11.86 USD with a low forecast of 9.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
-2.79% Downside
Current: 12.200
Low
9.00
Averages
11.86
High
15.00
-2.79% Downside
Current: 12.200
Low
9.00
Averages
11.86
High
15.00
JPMorgan
Rachel Vatnsdal
Overweight
maintain
$10 -> $14
2025-08-06
New
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$10 -> $14
2025-08-06
New
maintain
Overweight
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $14 from $10 and keeps an Overweight rating on the shares following the Q2 report. The firm believes momentum in the minimal residual disease business positions Adaptive for a strong back half of the year.
TD Cowen
Buy
maintain
$13 -> $15
2025-08-06
New
Reason
TD Cowen
Price Target
$13 -> $15
2025-08-06
New
maintain
Buy
Reason
TD Cowen raised the firm's price target on Adaptive Biotechnologies to $15 from $13 and keeps a Buy rating on the shares. The firm said they posted good results and noted guidance was raised and still see room for upside.
Piper Sandler
Overweight
maintain
$13 -> $15
2025-08-06
New
Reason
Piper Sandler
Price Target
$13 -> $15
2025-08-06
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $15 from $13 and keeps an Overweight rating on the shares. The firm notes Adaptive Biotechnologies achieved significant volume acceleration in its MRD business, and Piper believes a go-forward 30% revenue growth rate is achievable for multiple quarters, particularly as key drivers like EMR integrations gain further traction. This, coupled with continued ASP expansion, positions the company to drive revenue growth in the top quartile of Piper's coverage group.
BTIG
Buy
maintain
$11 -> $13
2025-07-29
Reason
BTIG
Price Target
$11 -> $13
2025-07-29
maintain
Buy
Reason
BTIG raised the firm's price target on Adaptive Biotechnologies to $13 from $11 and keeps a Buy rating on the shares. ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Craig-Hallum
John Wilkin
initiated
$15
2025-06-19
Reason
Craig-Hallum
John Wilkin
Price Target
$15
2025-06-19
initiated
Reason
Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies with a Buy rating and $15 price target.
Goldman Sachs
Salveen Richter
Hold
to
Strong Buy
Upgrades
$8 → $9
2025-03-21
Reason
Goldman Sachs
Salveen Richter
Price Target
$8 → $9
2025-03-21
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Adaptive Biotechnologies Corp (ADPT.O) is -16.35, compared to its 5-year average forward P/E of -12.79. For a more detailed relative valuation and DCF analysis to assess Adaptive Biotechnologies Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.79
Current PE
-16.35
Overvalued PE
-0.51
Undervalued PE
-25.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-17.33
Current EV/EBITDA
-64.58
Overvalued EV/EBITDA
-1.98
Undervalued EV/EBITDA
-32.67
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.61
Current PS
7.01
Overvalued PS
30.56
Undervalued PS
-1.33
Financials
Annual
Quarterly
FY2025Q2
YoY :
+36.33%
58.88M
Total Revenue
FY2025Q2
YoY :
-36.51%
-25.04M
Operating Profit
FY2025Q2
YoY :
-44.66%
-25.59M
Net Income after Tax
FY2025Q2
YoY :
-45.16%
-0.17
EPS - Diluted
FY2025Q2
YoY :
-31.25%
-13.09M
Free Cash Flow
FY2025Q2
YoY :
+26.56%
68.71
Gross Profit Margin - %
FY2025Q2
-40.35
FCF Margin - %
FY2025Q2
YoY :
-59.40%
-43.47
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
4.8M
USD
15
6-9
Months
6.4M
USD
5
0-12
Months
1.2K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.86% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.5M
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
5.7M
Volume
Months
6-9
2
2.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
4.8M
USD
15
6-9
Months
6.4M
USD
5
0-12
Months
1.2K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ADPT News & Events
Events Timeline
2025-08-05 (ET)
2025-08-05
16:54:45
Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)
2025-07-01 (ET)
2025-07-01
07:36:10
Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR
2025-05-30 (ET)
2025-05-30
07:35:34
Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress
Sign Up For More Events
Sign Up For More Events
News
9.5
08-06NASDAQ.COMPinnedWhy Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
4.0
08-08NASDAQ.COMAdaptive Biotechnologies Reaches Analyst Target Price
4.0
08-06BenzingaJP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $14
Sign Up For More News
People Also Watch
NXRT
NexPoint Residential Trust Inc
31.020
USD
-1.34%
GOOS
Canada Goose Holdings Inc
11.210
USD
-2.01%
PGRE
Paramount Group Inc
6.410
USD
-0.31%
DLX
Deluxe Corp
19.140
USD
-0.36%
SEAT
Vivid Seats Inc
16.760
USD
-6.53%
OPK
OPKO Health Inc
1.250
USD
+1.63%
BFC
Bank First Corp
116.450
USD
+0.78%
PHVS
Pharvaris NV
20.120
USD
-0.98%
AHH
Armada Hoffler Properties Inc
6.950
USD
+0.29%
TIXT
TELUS International (CDA) Inc
3.790
USD
+2.43%
FAQ
What is Adaptive Biotechnologies Corp (ADPT) stock price today?
The current price of ADPT is 12.2 USD — it has decreased -2.71 % in the last trading day.
What is Adaptive Biotechnologies Corp (ADPT)'s business?
What is the price predicton of ADPT Stock?
What is Adaptive Biotechnologies Corp (ADPT)'s revenue for the last quarter?
What is Adaptive Biotechnologies Corp (ADPT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Adaptive Biotechnologies Corp (ADPT)'s fundamentals?
How many employees does Adaptive Biotechnologies Corp (ADPT). have?